Verition Fund Management LLC Nektar Therapeutics Transaction History

Verition Fund Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.51 - $1.05 $843,318 - $1.74 Million	1,653,565 Added 1837.29%	1,743,565 $1.05 Million
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $47,700 - $92,700	90,000 New	90,000 $52,000
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $4,789 - $9,322	1,511 Added 14.77%	11,738 $45,000
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $42,544 - $140,314	10,227 New	10,227 $55,000
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $281,036 - $543,039	-19,422 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $308,227 - $449,036	19,422 New	19,422 $419,000
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $120,872 - $259,257	-7,148 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $221,588 - $259,472	7,148 New	7,148 $254,000
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $138,182 - $257,247	-4,541 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$46.46 - $68.49 $210,974 - $311,013	4,541 New	4,541 $277,000
Q2 2018 Aug 15, 2018	SELL	$46.25 - $104.45 $900,626 - $2.03 Million	-19,473 Closed	0 $0
Q1 2018 May 16, 2018	BUY	$57.4 - $108.44 $1.12 Million - $2.11 Million	19,473 New	19,473 $2.07 Million

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.